Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial

Rebecca H Haberman, Katrina A MacFarlane, Sydney Catron, Jonathan Samuels, Rebecca B Blank, Michael Toprover, Zakwan Uddin, Jiyuan Hu, Rochelle Castillo, Cinty Gong, Kun Qian, Vincent Piguet, Francisco Tausk, Jensen Yeung, Andrea L Neimann, Wayne Gulliver, Ralf G Thiele, Joseph F Merola, Alexis Ogdie, Proton Rahman, Soumya D Chakravarty, Lihi Eder, C T Ritchlin, Jose U Scher

Open source

DOI: 10.1136/bmjopen-2022-063650
Published: 2022-12
Container: BMJ Open
Publisher: BMJ
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/bmjopen-2022-063650,
  title = {Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial},
  author = {Rebecca H Haberman and Katrina A MacFarlane and Sydney Catron and Jonathan Samuels and Rebecca B Blank and Michael Toprover and Zakwan Uddin and Jiyuan Hu and Rochelle Castillo and Cinty Gong and Kun Qian and Vincent Piguet and Francisco Tausk and Jensen Yeung and Andrea L Neimann and Wayne Gulliver and Ralf G Thiele and Joseph F Merola and Alexis Ogdie and Proton Rahman and Soumya D Chakravarty and Lihi Eder and C T Ritchlin and Jose U Scher},
  year = {2022},
  journal = {BMJ Open},
  doi = {10.1136/bmjopen-2022-063650},
  url = {https://doi.org/10.1136/bmjopen-2022-063650}
}

RIS

TY  - JOUR
TI  - Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial
AU  - Rebecca H Haberman
AU  - Katrina A MacFarlane
AU  - Sydney Catron
AU  - Jonathan Samuels
AU  - Rebecca B Blank
AU  - Michael Toprover
AU  - Zakwan Uddin
AU  - Jiyuan Hu
AU  - Rochelle Castillo
AU  - Cinty Gong
AU  - Kun Qian
AU  - Vincent Piguet
AU  - Francisco Tausk
AU  - Jensen Yeung
AU  - Andrea L Neimann
AU  - Wayne Gulliver
AU  - Ralf G Thiele
AU  - Joseph F Merola
AU  - Alexis Ogdie
AU  - Proton Rahman
AU  - Soumya D Chakravarty
AU  - Lihi Eder
AU  - C T Ritchlin
AU  - Jose U Scher
PY  - 2022
JO  - BMJ Open
DO  - 10.1136/bmjopen-2022-063650
UR  - https://doi.org/10.1136/bmjopen-2022-063650
ER  -

APA

Haberman, R. H., MacFarlane, K. A., Catron, S., Samuels, J., Blank, R. B., Toprover, M., Uddin, Z., Hu, J., Castillo, R., Gong, C., Qian, K., Piguet, V., Tausk, F., Yeung, J., Neimann, A. L., Gulliver, W., Thiele, R. G., Merola, J. F., Ogdie, A., Rahman, P., Chakravarty, S. D., Eder, L., Ritchlin, C. T., & Scher, J. U. (2022). Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ Open. https://doi.org/10.1136/bmjopen-2022-063650

Source records

crossref · retrieved 2026-09-25T13:51:33.116Z